Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovo.

In search of novel therapeutic options to treat influenza virus (IV) infections, we previously identified a series of inhibitors that act by disrupting the interactions between the PA and PB1 subunits of the viral RNA polymerase. These compounds showed broad-spectrum antiviral activity against human influenza A and B viruses and a high barrier to the induction of drug resistance in vitro. In this short communication, we investigated the effects of combinations of the PA-PB1 interaction inhibitor 54 with oseltamivir carboxylate (OSC), zanamivir (ZA), favipiravir (FPV), and baloxavir marboxil (BXM) on the inhibition of influenza A and B virus replication in vitro. We observed a synergistic effect of the 54/OSC and 54/ZA combinations and an antagonistic effect when 54 was combined with either FPV or BXM. Moreover, we demonstrated the efficacy of 54 against avian IV strains both in cell culture and in the embryonated chicken eggs model. Finally, we observed that 54 enhances OSC protective effect against avian IV replication in the embryonated eggs model. Our findings represent an advance in the development of alternative therapeutic strategies against both human and avian IV infections.

• Publication year

  2024

• Venue

  Antiviral Research

• Publication date

  2024-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.antiviral.2024.105980PMID 39117284
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human neural progenitor cell models to study the antiviral effects and neuroprotective potential of approved and investigational human cytomegalovirus inhibitors.

  2024cited by this paper
• Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus Infection in Domestic Dairy Cattle and Cats, United States, 2024

  2024cited by this paper
• An orally active entry inhibitor of influenza A viruses protects mice and synergizes with oseltamivir and baloxavir marboxil

  2024cited by this paper
• The combined effect of oseltamivir and favipiravir on influenza a virus evolution in patients hospitalized with severe influenza.

  2023cited by this paper
• Discovery of N-substituted oseltamivir derivatives as novel neuraminidase inhibitors with improved drug resistance profiles and favorable drug-like properties.

  2023cited by this paper
• Antiviral Approaches against Influenza Virus

  2023cited by this paper
• Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy

  2023cited by this paper
• A comprehensive review of highly pathogenic avian influenza (HPAI) H5N1: An imminent threat at doorstep.

  2023cited by this paper
• Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022

  2023cited by this paper
• Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors via Targeting 150-Cavity.

  2022cited by this paper
• Alarming situation of emerging H5 and H7 avian influenza and effective control strategies

  2022cited by this paper
• Preclinical and clinical developments for combination treatment of influenza

  2022cited by this paper
• The Antifungal Drug Isavuconazole Inhibits the Replication of Human Cytomegalovirus (HCMV) and Acts Synergistically with Anti-HCMV Drugs.

  2021cited by this paper
• Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins

  2021cited by this paper
• Identification of C5-NH2 Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.

  2021cited by this paper
• 1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors.

  2021cited by this paper
• Favipiravir in Therapy of Viral Infections

  2021cited by this paper
• The Clinically Approved Antifungal Drug Posaconazole Inhibits Human Cytomegalovirus Replication

  2020cited by this paper
• In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses

  2020cited by this paper
• Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase

  2020cited by this paper
• Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.

  2020cited by this paper
• Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets

  2019cited by this paper
• Potent and broad‐spectrum cycloheptathiophene‐3‐carboxamide compounds that target the PA‐PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance

  2019cited by this paper
• In vitro characterization of baloxavir acid, a first‐in‐class cap‐dependent endonuclease inhibitor of the influenza virus polymerase PA subunit

  2018cited by this paper
• Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil

  2018cited by this paper
• Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.

  2018cited by this paper
• Efficient and regioselective one-step synthesis of 7-aryl-5-methyl- and 5-aryl-7-methyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivatives.

  2017cited by this paper
• Finding the right combination antiviral therapy for influenza.

  2017cited by this paper
• Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity.

  2017cited by this paper
• Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that Block Human Cytomegalovirus Replication.

  2016cited by this paper
• Clinical Implications of Antiviral Resistance in Influenza

  2015cited by this paper
• Treatment of hepatitis C: a systematic review.

  2014cited by this paper
• Antiviral combinations for severe influenza

  2014cited by this paper
• Favipiravir (T-705), a novel viral RNA polymerase inhibitor.

  2013cited by this paper
• Human Cytomegalovirus Inhibitor AL18 Also Possesses Activity against Influenza A and B Viruses

  2012cited by this paper
• Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase

  2012cited by this paper
• Efficacy of Combined Therapy with Amantadine, Oseltamivir, and Ribavirin In Vivo against Susceptible and Amantadine-Resistant Influenza A Viruses

  2012cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• Effects of the Combination of Favipiravir (T-705) and Oseltamivir on Influenza A Virus Infections in Mice

  2009cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults

  2001cited by this paper

• Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches

  2025cites this paper
• Avian flu: a swooping threat or just a volatile menace? What clinicians need to know.

  2025cites this paper
• H5N1 Avian Influenza: A Narrative Review of Scientific Advances and Global Policy Challenges

  2025cites this paper
• Anti-influenza drugs targeting trimeric RNA polymerase complex: From development to clinics

  2025influential citation